Alto Neuroscience (NYSE:ANRO) Reaches New 52-Week High – What’s Next?

Alto Neuroscience, Inc. (NYSE:ANRO) hit a new 52-week high on Friday . The company traded as high as $29.20 and last traded at $28.3680, with a volume of 942 shares trading hands. The stock had previously closed at $28.63.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ANRO. Wolfe Research began coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating on the stock. Zacks Research downgraded shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd. Bank of America assumed coverage on shares of Alto Neuroscience in a research note on Tuesday, May 5th. They set a “buy” rating and a $35.00 price target for the company. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a research report on Wednesday, June 17th. Finally, JonesTrading dropped their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Trading Down 3.7%

The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The company’s fifty day moving average price is $23.99 and its two-hundred day moving average price is $21.86. The firm has a market cap of $967.75 million, a PE ratio of -11.48 and a beta of 1.04.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, sell-side analysts forecast that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

Several hedge funds have recently modified their holdings of the business. Torren Management LLC acquired a new position in Alto Neuroscience during the fourth quarter worth $62,000. GK Wealth Management LLC purchased a new position in Alto Neuroscience in the second quarter worth $226,000. Balyasny Asset Management L.P. purchased a new position in Alto Neuroscience in the fourth quarter worth $198,000. OMERS ADMINISTRATION Corp acquired a new stake in Alto Neuroscience in the fourth quarter valued at $221,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in Alto Neuroscience in the fourth quarter valued at $304,000.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.